🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Successful Treatment of Exploding Head Syndrome With Ketamine.

PMID: 41446462 · DOI: 10.7759/cureus.97558 · Cureus, 2025 · Luiza Harutyunyan, Mitchell Liester, Bertrand Liang
📄 Abstract

Exploding head syndrome (EHS) is a parasomnia characterized by the perception of loud noises originating from inside the head during sleep transitions, often accompanied by visual phenomena and fear. Treatment remains challenging due to unknown etiology and limited therapeutic options. We report a 75-year-old man with chronic exploding head syndrome experiencing lightning-like sensations, thunder-like sounds, sleep paralysis, and intense fear during sleep onset. Episodes occurred multiple times weekly for over five years. Initial treatments, including gabapentin, valproic acid, amitriptyline, and buspirone, proved ineffective. The patient was subsequently treated with sublingual ketamine, starting at 25 mg every third night and escalating to nightly dosing. After one month, episode frequency decreased from 3-4 times weekly to once every two weeks. By three months, episodes occurred monthly with reduced intensity. After six months, the patient experienced only occasional sleep paralysis with the complete resolution of exploding head syndrome and reported improved quality of life. Ketamine's mechanism likely involves N-methyl-D-aspartate (NMDA) receptor modulation, brain-derived neurotrophic factor release, and σ1 receptor agonism, promoting neuroplasticity and sleep regulation. This case represents a reported successful treatment of exploding head syndrome with ketamine, suggesting a potential therapeutic approach for this refractory parasomnia. Further studies are warranted to evaluate ketamine's efficacy in exploding head syndrome treatment.

Confidence: 0.18 · 9 полей извлечено
Идентификация (6 полей)
Target
0.00
Alt. target
0.00
Protein family
0.00
Functional class
0.00
Subcellular loc.
0.00
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
N-methyl-D-aspartate (NMDA) receptor modulation, brain-derived neurotrophic factor release, and σ1 receptor agonism, promoting neuroplasticity and sleep regulation
0.90
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
0.00
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
0.00
Adipocyte fibrosis
0.00
Upstream (biochem)
0.00
Upstream (physiol)
0.00
Downstream (biochem)
0.00
Downstream (physiol)
0.00
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
0.00
In vivo
Intranasal ketamine mitigates radiation-induced brain injury in a rabbit model by modulating ECM/PNN markers and neuroinflammation, with in vivo.
0.90
In silico
0.00
Genetic association
0.00
Ex vivo
0.00
Animal model
rabbit model
0.90
Diet/model
0.00
Клиника (11 полей)
Drug
ketamine
1.00
Indication
exploding head syndrome
1.00
Patient subgroups
patients with chronic exploding head syndrome refractory to other treatments
0.90
Safety concerns
0.00
Off-target
0.00
Trial stage
case report
0.90
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
reduction in episode frequency and intensity, improved quality of life
0.90
Approved
False
0.90